News

Researchers found CU was associated with increased odds of developing anxiety, depression, PTSD, and substance use disorder, among other conditions.

Recent research presented at the 2025 RAD Meeting explored the use of ruxolitinib cream in combination with systemic therapy.

Treatment with rupatadine led to improvements in CSU and chronic inducible urticaria.

Discover the revolutionary Hydrafacial HydraFillic with Pep9 Booster, enhancing skin hydration and reducing fine lines with advanced peptide technology.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Almirall is pioneering a holistic approach in dermatology, emphasizing psychological well-being through the WHO-5 index in clinical trials.

The monoclonal anti-KIT antibody exhibited promise in adults with moderate to severe antihistamine-refractory CSU.

Explore the top headlines of the week including insights on the latest clinical trials, therapeutic updates, and more.

Test your knowledge of key words and terms associated with dermatology news from the previous week.

In case you missed it, this week we had news about denifanstat's promising phase 3 results for acne, emerging therapies in lichen planus, initial insights from RAD 2025, and more.

This week, we feature top articles from our sister publications on regulatory updates, clinical trial insights, and more.

Raj Chovatiya, MD, PhD, MSCI, discussed his approach to personalizing treatment dosing plans with adult patients based on skin clearance and therapeutic type at RAD 2025.

At RAD 2025, Brad Glick, DO, MPH, reviewed the clinical signs of topical steroid withdrawal, the need for detailed patient histories to distinguish it from severe AD flares, and the role of targeted non-steroidal and systemic therapies.

At RAD 2025, Vimal H. Prajapati, MD, shared phase 4 data from the CAN UpTIMISE study that shows switching to upadacitinib after inadequate response with dupilumab achieved rapid and significant improvements in skin clearance, itch, and QOL.

At the 2025 Revolutionizing Atopic Dermatitis Conference, JiaDe “Jeff” Yu, MD, MS, discussed the multifactorial nature of chronic hand eczema, highlighting its distinction from atopic dermatitis.

At the 2025 Revolutionizing Atopic Dermatitis Conference, Gil Yosipovitch, MD, explored the pathophysiology of chronic itch through the lens of type 2 cytokine inhibition, neuromodulatory therapies, and more.

Catch up on coverage from the final day of the 2025 Revolutionizing Atopic Dermatitis Conference held in Nashville, Tennessee.

At RAD 2025, Christopher Bunick, MD, PhD, presented 6-month data from the CorEvitas AD Registry, highlighting clinically meaningful skin clearance, itch reduction, and more in bio-naïve and bio-experienced adults treated with upadacitinib.

At RAD 2025, Eli Lilly revealed promising results for lebrikizumab in treating atopic dermatitis in patients with skin of color.

At RAD 2025, pediatric dermatologist Lisa Swanson, MD, and allergist Anne Marie Singh, MD, led a dual session aimed at demystifying the connection between food allergy and atopic dermatitis.

At the 2025 Revolutionizing Atopic Dermatitis Conference, Leon Kircik, MD, highlighted the safety of JAK inhibitors, clarified misconceptions around boxed warnings, and discussed the clinical relevance of recent label updates for abrocitinib.

At RAD 2025, Tiffany Mayo, MD, emphasized the need for clinicians to recognize shared inflammatory mechanisms between AD and AA.

Data presented at the 2025 RAD Conference shows dupilumab improves daily functioning, mental health, and social aspects in patients with atopic dermatitis.

Catch up on coverage from the first day of the 2025 Revolutionizing Atopic Dermatitis Conference held in Nashville, Tennessee.

At RAD 2025, Mona Shahriari, MD, emphasized the cumulative life course impairment of AD in pediatric and adult patients, highlighting its impact on sleep, mental health, family well-being, and quality of life.

Discover groundbreaking insights from the RAD 2025 conference on roflumilast's potential to transform treatment for infant atopic dermatitis.

At RAD 2025, Jonathan Silverberg, MD, PhD, MPH, provided an in-depth look at the clinical integration of newly approved biologics nemolizumab and lebrikizumab in AD.

A poster at RAD 2025 detailed the patient-reported outcomes across skin types and racial groups.

Co-chairs Jonathan Silverberg, MD, PhD, MPH, and Raj Chovatiya, MD, PhD, MSCI, gave insight into what attendees can look forward to at this year's meeting.

Arcutis Biotherapeutics showcases promising long-term results of Zoryve for atopic dermatitis in young children at RAD 2025, emphasizing safety and efficacy.